Presented By: Creative Educational Concepts, Inc. Lexington, KY
|
|
- Mark Goodwin
- 5 years ago
- Views:
Transcription
1
2 Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of April The content and views presented in this educational activity are those of the authors/presenters and do not necessarily reflect those of Creative Educational Concepts or the supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and offlabel uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies or strategies described in this educational activity.
3 Usage Rights This slide deck is provided for educational purposes and slides may be used for personal, non-commercial presentations only as long as content and references remain the same. No part of this slide deck may be published or distributed in print or electronic format without prior written permission from Creative Educational Concepts.
4 Presented By: Creative Educational Concepts, Inc. Lexington, KY
5 Special Thanks! Supported through an independent educational grant from: AstraZeneca
6 Navigating the Guidelines: Updates in Antihyperglycemic Therapies and ADA/EASD and AACE Guidelines in 2015 Stuart T. Haines, PharmD, BCPS, BCACP, BC-ADM Professor and Vice Chair for Clinical Services University of Maryland School of Pharmacy Baltimore, MD
7 Case Study DR is a 62-year-old African American female presenting to the Medication Therapy Management Clinic for a medication review Chief Complaint: I have diabetes, and my blood glucose isn t doing so well Past Medical History: Type 2 Diabetes Mellitus (T2DM), Hypertension, Dyslipidemia, Obesity, Carpal Tunnel Syndrome
8 Case Study (cont.) Medications Aspirin 81 mg orally daily Amlodipine 5 mg orally daily Lisinopril 10 mg orally daily Atorvastatin 20 mg orally daily Calcium + Vitamin D supplement 1 tablet orally twice daily Ibuprofen as needed for headaches and joint pain
9 Case Study (cont.) Social History Comprehensive health plan through work Prescription drug plan 3 tiers ($10/$25/40%) High school teacher (hoping to retire soon) Drinks socially (2-3/month) Does use tobacco products/smoke Lives with husband; grown children and grandchild live nearby
10 Case Study (cont.) Subjective Data Nocturia 1-2 times per night; denies excessive thirst or weight loss Physical Exam BP=142/78 mmhg Pulse=88 bpm, regular Weight=230 lbs Height=65 BMI=38.3 kg/m 2
11 Case Study (cont.) Laboratory Tests (1 week ago) Na=141 meq/l K=4.6 meq/l BUN=14 mg/dl SCr=1.1 mg/dl Glucose=157 mg/dl A1C=8.7% AST=34 units/l ALT=26 units/l Total Cholesterol=151 mg/dl (LDL=87 mg/dl; HDL=34 mg/dl; TG=178 mg/dl)
12 Pathophysiology of Diabetes Impaired GI motility and incretin effect GI Tract Defective -cell function Pancreas Diminished or absent insulin and amylin release Brain Insulin resistance Reduced glucose uptake Muscle Liver Excess glucose production Scheen AJ. Acta Clin Belg. 2003; DeFronzo RA, et al. Diabetes Care
13 Treatment Approach to T2DM Dietary changes Reduce consumption of calories Reduce consumption of simple carbohydrates Increase physical activity Medications Improve insulin secretion Mitigate insulin resistance Reduce hepatic glucose production Increase urinary glucose excretion DeFronzo RA, et al. Diabetes Care
14 Treatment Options T2DM Medications Approved before 2000 Exogenous insulin (human and analogs) Sulfonylureas Biguanides (metformin) Alpha-glucosidase inhibitors (AGIs) Meglitinides Thiazolidinediones (TZDs) Stein SA, et al. Expert Opin Drug Saf. 2013; Fowler MJ. Clin Diabetes
15 Treatment Options T2DM Medications Approved since 2005! Amylin analogues (pramlintide) Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) Bile acid sequestrant (colesevelam) Dopamine agonist (bromocriptine) Sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) Stein SA, et al. Expert Opin Drug Saf. 2013; Fowler MJ. Clin Diabetes
16 ADA Standards of Medical Care in Diabetes (2015) METFORMIN American Diabetes Association. Diabetes Care
17 ADA Standards of Medical Care in Diabetes (2015) Dual and Triple Therapy METFORMIN Sulfonylurea Thiazolidinedione DPP-4 Inhibitor SGLT2 Inhibitor GLP-1 RA Basal Insulin In 2 or 3 drug combinations American Diabetes Association. Diabetes Care
18 ADA Standards of Medical Care in Diabetes (2015) Injectable Therapy METFORMIN Basal Insulin Prandial Insulin OR GLP-1 RA American Diabetes Association. Diabetes Care
19 AACE Glycemic Control Algorithm (2013) Garber AJ, et al. Endocr Pract
20 AACE Glycemic Control Algorithm (2013) Preferred 1 st line agents Metformin (use unless contraindicated) DPP-4 Inhibitors GLP-1 RAs AGIs Preferred add-on agents Colesevelam Bromocriptine Garber AJ, et al. Endocr Pract
21 Metformin Cornerstone of Therapy Affordable Positive/neutral impact on weight Low risk of hypoglycemia GI side effects can be managed Risk of lactic acidosis far less than feared Effectively lowers blood glucose and A1C alone or in combination with other treatments Reduces risk of diabetes complications Inzucchi SE, et al. JAMA. 2014; UK Prospective Diabetes Study (UKPDS) Group. Lancet
22 My Ideal Add-On Agent Effective gets to goal BG and A1C Well tolerated and safe Addresses multiple metabolic abnormalities Promotes weight loss Durable glycemic effect Reduces risk of diabetes-related complications and death Oral, once daily, and inexpensive
23 Practical Applications for the Appropriate Use of GLP-1 Receptor Agonists to Optimize Glycemic Control Dawn Fuke, PharmD, BCPS Primary Care Clinical Pharmacy Specialist Clinical Pharmacy Providence Medical Group Portland, OR
24 Notes
25 GLP-1 Receptor Agonists GLP-1: incretin secreted by intestinal L cells GLP-1 receptors Satiety Appetite Slows gastric emptying Insulin release Glucagon release Donnelly D. Br J Pharmacol
26 GLP-1 Receptor Agonists (cont.) Exenatide 5-10 mcg twice daily (Byetta 2005) 2 mg once weekly (Bydureon 2012) Liraglutide mg daily (Victoza 2010) 3 mg daily (weight loss indication, Saxenda 2014) Albiglutide mg once weekly (Tanzeum 2014) Dulaglutide mg once weekly (Trulicity 2014) Lixisenatide (anticipated FDA submission 2015)
27 GLP-1 RAs: Exenatide: 2 trials (N=1,156) Liraglutide: 1 trial (N=746) Dulaglutide: 1 trial (N=807) Albiglutide: no monotherapy trials Monotherapy 4 studies: GLP-1 RAs vs. placebo or active control Active control: Glimepiride 8 mg/day Metformin 1,500-2,000 mg/day Pioglitazone 45 mg/day Sitagliptin 100 mg/day weeks Moretto TJ, et al. Clin Ther. 2008; Russell-Jones D, et al. Diabetes Care. 2012; Garber A, et al. Lancet. 2009; Umpierrez G, et al. Diabetes Care
28 Exenatide Monotherapy: Results Dose A1C (%) 5-10 mcg twice daily to -0.9 FPG (mg/dl) to PPG (mg/dl) to Weight (kg) -2.8 to Placebo Exenatide 2 mg/week N/A -2.0 Metformin 2,000 mg/day N/A -2.0 Pioglitazone 45 mg/day N/A 1.5 Sitagliptin 100 mg/day N/A -0.8 Exenatide twice daily: more effective in glycemic control and weight loss compared to placebo Exenatide once weekly Glycemic control: as effective as metformin; more effective than sitagliptin; not noninferior to pioglitazone Weight loss: more effective than sitagliptin and pioglitazone; similar to metformin FPG=Fasting Plasma Glucose; PPG=Postprandial Glucose Moretto TJ, et al. Clin Ther. 2008; Russell-Jones D, et al. Diabetes Care
29 Monotherapy: Results Dose A1C (%) FPG (mg/dl) Liraglutide mg/day -1.0 to to -26 PPG (mg/dl) to Weight (kg) -2.1 to -2.8 Glimepiride 8 mg/day Dulaglutide Metformin mg/week 1,500-2,000 mg/day to to to to to Liraglutide: more effective in glycemic control and weight loss compared to glimepiride Dulaglutide: as effective in glycemic control and weight loss as metformin Garber A, et al. Lancet. 2009; Umpierrez G, et al. Diabetes Care
30 GLP-1 Receptor Agonist Monotherapy Glycemic control: More effective than placebo, DPP-4 inhibitors and sulfonylureas As effective as metformin Not noninferior to TZD Weight loss: More effective than placebo, DPP-4 inhibitors, TZD and sulfonylureas As effective as metformin
31 Combination with Metformin 7 studies: metformin + GLP-1 RAs vs. metformin + placebo or active control GLP-1 RA: Exenatide: 2 trials (N=850) Liraglutide: 3 trials (N=2,351) Dulaglutide: 2 trials (N=1,697) Albiglutide: 1 trial (N=1,012) Active control: Glimepiride 2-4 mg/day Pioglitazone 45 mg/day Sitagliptin 100 mg/day weeks DeFronzo RA, et al. Diabetes Care. 2005; Bergenstal RM, et al. Lancet. 2010; Nauck M, et al. Diabetes Care. 2009; Pratley R. Int J Clin Pract. 2011; Nauck M, et al. Diabetes Care. 2014; Dungan KM, et al. Lancet. 2014; Ahrén B, et al. Diabetes Care
32 Exenatide Exenatide + Metformin Dose A1C (%) 5-10 mcg twice daily -0.4 to -0.8 FPG (mg/dl) -7.2 to PPG (mg/dl) Weight (kg) ~ to -2.8 Placebo ~ Exenatide 2 mg/week N/A -2.3 Pioglitazone 45 mg/day N/A 2.8 Sitagliptin 100 mg/day N/A -0.8 Metformin + Exenatide twice daily: more effective in glycemic control and weight loss compared to placebo Metformin + Exenatide once weekly: Glycemic control: More effective than pioglitazone (A1C) and sitagliptin (A1C and FPG) Weight loss: More effective than pioglitazone and sitagliptin DeFronzo RA, et al. Diabetes Care. 2005; Bergenstal RM, et al. Lancet
33 Liraglutide Liraglutide + Metformin Dose A1C (%) mg/day FPG (mg/dl) -1 to PPG (mg/dl) to Weight (kg) -2.6 to -3.6 Placebo Glimepiride 4 mg/day -0.4 to Liraglutide mg/day to to -37 N/A -2.8 to -3.6 Sitagliptin 100 mg/day N/A Metformin + Liraglutide Glycemic control: More effective than placebo and sitagliptin As effective as glimepiride Weight loss: More effective than placebo, glimepiride and sitagliptin Nauck M, et al. Diabetes Care. 2009; Pratley R, et al. Int J Clin Pract
34 Dulaglutide + Metformin Dose A1C (%) FPG (mg/dl) PPG (mg/dl) Dulaglutide mg/week to to -43 N/A Weight (kg) -2.6 to Placebo N/A -1.5 Sitagliptin 100 mg/day N/A Dulaglutide mg/week Liraglutide mg/day Metformin + Dulaglutide: Glycemic control: More effective than placebo and sitagliptin As effective as liraglutide Weight loss: More effective than placebo and sitagliptin Less effective than liraglutide Nauck M, et al. Diabetes Care. 2014; Dungan KM, et al. Lancet
35 Albiglutide + Metformin Dose A1C (%) FPG (mg/dl) PPG (mg/dl) Weight (kg) Albiglutide mg/week N/A Placebo N/A -1.0 Glimepiride 2-4 mg/day N/A 1.17 Sitagliptin 100 mg/day N/A Metformin + Albiglutide: Glycemic control: More effective than placebo, glimepiride and sitagliptin Weight loss: More effective than glimepiride Not significant compared to placebo or sitagliptin Nauck M, et al. Diabetes Care. 2014; Dungan KM, et al. Lancet
36 GLP-1 RAs with Metformin Glycemic control: More effective than placebo, TZD, and DPP-4 inhibitors As effective as sulfonylureas Liraglutide similar to dulaglutide Weight loss: More effective than placebo, sulfonylureas, TZD, and DPP-4 inhibitors Liraglutide more effective than dulaglutide
37 Triple Therapy 7 studies added GLP-1 RAs to metformin + an additional oral antidiabetic agent (N=4,369) Glycemic control: A1C reductions (-0.8 to -1.3%) More effective than placebo As effective as TZD and insulin Weight loss: -0.4 to -2.3 kg More effective than TZD or insulin Kendall DM, et al. Diabetes Care. 2005; Home PD, et al. Diabetes Obes Metab. 2015; Heine RJ, et al. Ann Intern Med. 2005; Russell-Jones D, et al. Diabetologia. 2009; Wysham C, et al. Diabetes Care. 2014; Zinman B, et al. Diabetes Care. 2009; Reusch J, et al. Diabetes Obes Metab
38 GLP-1 RAs vs. Insulin Glargine 4 randomized open-label trials (N=2,333) Exenatide twice daily, exenatide weekly, liraglutide or albiglutide No studies comparing dulaglutide Stable on oral diabetes medications Insulin glargine titrated to FPG <100 mg/dl HARMONY 4 (albiglutide): glargine 10 units/day weeks Heine RJ, et al. Ann Intern Med. 2005; Diamant M, et al. Lancet. 2010; Russell-Jones D, et al. Diabetologia. 2009; Weissman PN, et al. Diabetologia
39 GLP-1 RAs vs. Insulin Glargine Dose A1C (%) Glycemic control: Similar A1C reductions FPG reduction greater with insulin glargine PPG reduction greater with GLP-1 RAs Weight: GLP-1 RAs more effective FPG (mg/dl) PPG (mg/dl) Weight (kg) Exenatide 10 mcg twice daily Exenatide 2 mg/week Liraglutide 1.8 mg/day Albiglutide 30 mg/week N/A Insulin Glargine to to to to 1.8 Heine RJ, et al. Ann Intern Med. 2005; Diamant M, et al. Lancet. 2010; Russell-Jones D, et al. Diabetologia. 2009; Weissman PN, et al. Diabetologia
40 GLP-1 RA vs. Prandial Insulin HARMONY 6: albiglutide vs. insulin lispro Randomized, open-label trial (N=563) Insulin glargine + oral diabetes agents Metformin, pioglitazone, and/or AGIs Sulfonylureas, glinides, and DPP-4 inhibitors d/c 1 week prior to start Dose A1C (%) FPG (mg/dl) Glycemic control noninferior to lispro Weight change significant vs. lispro PPG (mg/dl) Weight (kg) Albiglutide 30 mg/week N/A -0.7 Insulin Lispro Prandial N/A 0.8 Rosenstock J, et al. Diabetes Care
41 Head to Head Comparisons 7 direct comparison trials (N=4,311) Randomized, open-label Noninferiority design Some superiority analyses in specific trials Various oral glucose lowering agent combinations weeks Buse JB, et al. Lancet. 2009; Buse J, et al. Lancet. 2013; Dungan KM, et al. Lancet. 2014; Pratley RA, et al. Lancet Diabetes Endocrinol. 2014; Drucker DJ, et al. Lancet. 2008; Blevins T, et al. J Clin Endocrinol Metab. 2011; Wysham C, et al. Diabetes Care
42 Exenatide Twice Daily: Head to Head 4 studies: exenatide twice daily (N=2,444) Dose A1C (%) FPG (mg/dl) PPG (mg/dl) Glycemic control: Less effective: exenatide weekly, liraglutide, dulaglutide Weight: Less effective: liraglutide, dulaglutide 1.5 mg dose Similar efficacy: exenatide weekly Weight (kg) Exenatide 10 mcg twice daily -0.8 to to to -3.6 Exenatide 2 mg/week -1.6 to to -41 N/A -2.3 to -3.7 Liraglutide 1.8 mg/day N/A Dulaglutide mg/week to to to to 0.2 Drucker DJ, et al. Lancet. 2008; Blevins T, et al. J Clin Endocrinol Metab. 2011; Buse J, et al. Lancet. 2013; Wysham C, et al. Diabetes Care
43 Liraglutide: Head to Head 4 studies: liraglutide (N=2,786) Dose A1C (%) FPG (mg/dl) Glycemic control: More effective: exenatide twice daily and weekly, albiglutide Noninferior: dulaglutide Weight: More effective: exenatide weekly, dulaglutide, albiglutide PPG (mg/dl) Weight (kg) Liraglutide 1.8 mg/day to to to to Exenatide 10 mcg twice daily Exenatide 2 mg/week N/A Dulaglutide 1.5 mg/week Albiglutide mg/week N/A Buse JB, et al. Lancet. 2009; Buse J, et al. Lancet. 2013; Dungan KM, et al. Lancet. 2014; Pratley RA, et al. Lancet Diabetes Endocrinol
44 Overall Efficacy Glycemic control: Monotherapy, combination with oral antidiabetic agents and basal insulin % reduction in baseline A1C Up to ~60 mg/dl decrease in FPG and PPG Weight: Up to 3.6 kg weight loss
45 Side Effects and Safety Side effects Nausea and gastrointestinal symptoms most common (up to 30%) Headache (up to 13%) Hypoglycemia (more common in combination therapy) Injection site reactions (more common with exenatide once weekly and albiglutide) Safety Acute pancreatitis/pancreatic cancer Medullary thyroid carcinoma FDA Prescribing Information.
46 Steering Patients through Medication Therapy Management: Case-Based Strategies to Improve Medication Use in Your Patients Nicholas Leon, PharmD, BCPS, BCACP Assistant Professor, Department of Pharmacy Practice Thomas Jefferson University Philadelphia, PA
47 Practical Considerations Is this the best type of medication for this patient? Is this an appropriate therapy for this patient? Is this the right therapy for this patient? Potential additional benefits Mitigating adverse effects Potential long term risks Will the patient have access to this medication? Cost issues Formulary considerations Will the patient be able to use this medication appropriately? Drug administration technique Initiating and titrating these drugs Monitoring therapy
48 Primary Benefits of GLP-1 Receptor Agonists Monotherapy or add on therapy for type 2 diabetes A1C by 1-1.7% Avoidance of hypoglycemia insulin secretion in a glucosedependent manner glucagon secretion similarly May need to dose of insulin or insulin secretagogue to reduce the risk of hypoglycemia Can be used with elevated PPG and FPG Mechanism really focuses in on PPG Avoidance of weight gain/ promotion of weight loss Promote a 1-4 kg weight loss in most Promotion of satiety appetite and food intake Pts appear to maintain weight loss while on therapy Nauck MA. Diabetes Care
49 Potential Additional Benefits Decrease in systolic blood pressure of 2-7 mmhg Improved endothelial function Enhanced natriuresis and fluid excretion Vasodilation Effect on triglycerides -12 to -40 mg/dl Nauck MA. Diabetes Care
50 GI Adverse Effects: Head to Head LEAD 6 N Mean Exposure Nausea % Diarrhea % Vomiting % # of pt withdrawals due to nausea Liraglutide 1.8 mg 235 Exenatide 10 mcg twice daily 26 weeks patients patients DURATION 6 N Mean Exposure Nausea % Diarrhea % Vomiting % # of pt withdrawals due to GI ADEs Liraglutide 1.8 mg 450 Exenatide 2 mg once weekly 26 weeks patients patients ADE=Adverse Drug Event Buse JB, et al. Lancet. 2009; Buse J, et al. Lancet
51 GI Adverse Effects: Head to Head AWARD 6 N Mean Exposure Nausea % Diarrhea % Vomiting % # of pt withdrawals due to GI ADEs Liraglutide 1.8 mg patients 26 weeks Dulaglutide 1.5 mg patients HARMONY 7 N Mean Exposure Nausea % Diarrhea % Vomiting % # of pt withdrawals due to GI ADEs Liraglutide 1.8 mg patients 32 weeks Albiglutide 50 mg patients Dungan KM, et al. Lancet. 2014; Pratley RA, et al. Lancet Diabetes Endocrinol
52 Mitigation of Common Adverse Effects Nausea Usually mild moderate Peaks within 4-10 weeks Resolves in all but ~10% of cases in a similar time frame Within 28 weeks with exenatide twice daily Hypoglycemia Depends on background therapy Mostly in combination with insulin and insulin secretagogues May need to decrease the dose of insulin or insulin secretagogue to reduce the risk of hypoglycemia Nauck MA. Diabetes Care
53 Injection Site Reactions LEAD 6 Skin and Subcutaneous Tissue Disorders General Disorders and Administration Site Conditions Liraglutide 1.8 mg 3.4% 8.9% Exenatide 10 mcg twice daily 6.9% 9.1% DURATION 6 Subcutaneous Nodule Injection Site Erythema Injection Site Pruritus Liraglutide 1.8 mg 0% <1% <1% Exenatide 2 mg once weekly 4% 2% 3% Buse JB, et al. Lancet. 2009; Buse J, et al. Lancet
54 Injection Site Reactions Liraglutide 1.8 mg Dulaglutide 1.5 mg AWARD 6 Injection-site reactions were uncommon in both groups. HARMONY 6 Injection Site Reaction Liraglutide 1.8 mg 5.4% Albiglutide 50 mg 12.9% Dungan KM, et al. Lancet. 2014; Rosenstock J, et al. Diabetes Care
55 Acute Pancreatitis Meta-analysis: BMJ RCTs; 14,562 patients Median 26 weeks Range total events in experimental group 0.11% event rate OR 1.05; 95% CI Li L, et al. BMJ
56 Medullary Thyroid Carcinoma (MTC): Black Box Warning Rodents C-cell lines are equipped with 22 to 45 fold more GLP-1 receptors than humans Pre-clinical studies showed proliferative changes in thyroid C cells Dose dependent increases of calcitonin in rodents given liraglutide Diabetes and Cancer an AACE/ACE Consensus Statement 2013 Exenatide twice daily 0.3 cases per 100 patient-years vs. zero cases per 100 patient-years for comparators Exenatide once weekly No cases of MTC were reported in Europe Liraglutide Calcitonin did not increase in liraglutide treated patients 1.3 cases per 1,000 patient-years vs. 1.0 cases per 1,000 patient-years Handelsman Y, et al. Endocr Pract
57 Risk Evaluation and Mitigation Strategies (REMS) For acute pancreatitis and the potential risk of medullary thyroid carcinoma Communication plan only Exenatide once weekly, liraglutide, dulaglutide, albiglutide No REMS Exenatide twice daily released from requirement 8/5/ PatientsandProviders/ucm htm.
58 Exenatide twice daily Exenatide once weekly Initiation and Titration Initial Dose 5 mcg for 1 month Treatment Dose Maximum Dose 10 mcg 10 mcg 2 mg Dose Adjustments CrCl <30 ml/min: Not recommended Comments Within 60 minutes prior to a meal Liraglutide daily Albiglutide once weekly Dulaglutide once weekly 0.6 mg for 1 week 30 mg 0.75 mg 1.2 mg 1.8 mg* 30 or 50 mg 0.75 or 1.5 mg 50 mg None None; Limited experience with renal impairment Missed dose, administer as soon as possible if within 3 days 1.5 mg None recommended *May need to decrease dose of insulin or insulin secretagogue to reduce the risk of hypoglycemia FDA Prescribing Information.
59 Exenatide Twice Daily and Liraglutide Administration Actual administration of dose is much like an insulin pen Available in prefilled syringes Store unused pens in refrigerator Store used pens at room temperature (up to 30 days after 1 st use) Need to attach 4, 5, or 6 mm pen needle Inject in subcutaneous tissue in abdomen, thigh or arm FDA Prescribing Information.
60 Exenatide Once Weekly Administration (Pen) Hold pen upright Assure liquid in inspection window is clear Attach needle Twist knob on bottom until you hear a click Green label should disappear Tap pen against palm of hand firmly Rotate every 10 taps May need to tap more than 80 times Look through inspection window to assure thoroughly mixed Should be uniformly cloudy Once mixed, twist knob again until you hear a click Orange label should disappear Injection button will appear from bottom Push injection button to administer dose FDA Prescribing Information.
61 Albiglutide Administration Viewing window should display the # 1 Twist until you hear a click see # 2 in viewing window Rock pen side to side gently 5 times do not shake Wait 30 minutes for medication to dissolve Rock pen side to side gently 5 times Viewing window should be clear Attach needle by pushing down hear click and feel snap Tap for air bubbles 2-3 times Twist pen to prime device see # 3 in viewing window Push injection button to administer FDA Prescribing Information.
62 Dulaglutide Administration (Pen) Needle comes already attached Remove base cap, hold to skin Turn indicator to the right unlocks pen Press green button hear click Hold pen in place for 5-10 seconds until second click is heard Throw device in sharps container FDA Prescribing Information.
63 Formulary Considerations Safety GI ADEs Injection site reactions are more common than with insulin Efficacy Lack of comparative trials with patient-important long-term outcomes Microvascular or macrovascular complications Health-related quality of life Mortality
64 Formulary Considerations Cost What the health plan assumes What the patient assumes Used before other oral therapies? Cost of other oral agents Cost of potential increased self-monitoring of blood glucose (SMBG) with insulin secretagogues Cost of hypoglycemia Used instead of insulin? Consider total cost Cost of insulin(s) Insulin pen needles Cost of increased SMBG with use of intermediate or rapid acting insulin Cost of hypoglycemia Ease of Use What about our patient DR???
65 Importance of Education
66
GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationAdvances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D
Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with
More informationNew Drug Evaluation: Dulaglutide
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationAlbiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes
St. Onge et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 10 REVIEW ARTICLE Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St. Onge 1*, Shannon
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationProgressive Loss of β-cell Function in T2DM
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of November 2015. The content and views presented in this educational activity are those of
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationNew Treatment Options for Type 2 Diabetes: Incretin-Based Therapy
New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy New Treatment Options for Type 2 Diabetes: Incretin-Based Therapy is supported by an educational grant from Novo Nordisk Inc. This program
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationDisclosures. Objectives. Objectives. Maximizing the Role of GLP-1 Agonists in Our Patients with. Incretin Glucose Regulation
Disclosures Maximizing the Role of GLP-1 Agonists in Our Patients with Type 2 Diabetes Curtis L. Triplitt, Pharm.D., CDE Associate Director, Diabetes Research Center, Texas Diabetes Institute Associate
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationGLP-1-based therapies in the management of type 2 diabetes
GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationDiabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationSelecting GLP-1 RA Treatment
Selecting GLP-1 RA Treatment Dr Felicity Kaplan March 2017 Objectives Review the progressive nature of type 2 diabetes Understand the need for timely treatment intensification Examine the place of GLP-1
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationGlucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
580257TAE0010.1177/2042018815580257Therapeutic Advances in Endocrinology and MetabolismSH Tella and MS Rendell research-article2015 Therapeutic Advances in Endocrinology and Metabolism Review Glucagon-like
More informationGLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED
More informationUpdate on GLP-1 Agonists in Type 2 Diabetes is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the American
Update on GLP-1 Agonists in Type 2 Diabetes is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the American Association of Diabetes Educators (AADE) for nurses, dietitians,
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationApproaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster
Non-Insulin Injectable Agents Approaches to Addressing Incretin Deficiency Longer-acting analogs? (Incretin mimetics) GLP-1 Analogs Inhibition of inactivation? (Incretin enhancers) DPP-4 Inhibitors Drucker
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationGlucagon-Like Peptide-1 (GLP-1) Agonists
Glucagon-Like Peptide-1 (GLP-1) Agonists Policy Number: 5.01.565 Last Review: 07/2018 Origination: 06/2014 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace See Important
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationInjectable Agents for Type 2 Diabetes. Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017
Injectable Agents for Type 2 Diabetes Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017 Financial Disclosures Sanofi speaker honoraria No other relevant financial disclosures Injectable
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More information3/22/2017. Type 2 Diabetes Pathophysiology and Pharmacology Review. Accreditation Statement
Type 2 Diabetes Pathophysiology and Pharmacology Review Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA This
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationJoshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationDiabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items
Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:
More informationNew Drug Evaluation: lixisenatide injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationIt is estimated that approximately 20.8 million Americans
FORMULARY MANAGEMENT Managed Care Perspective on Three New Agents for Type 2 Diabetes Shawna VanDeKoppel, PharmD; Hae Mi Choe, PharmD, CDE; and Burgunda V. Sweet, PharmD, FASHP ABSTRACT BACKGROUND: Despite
More informationDate of Review: September 2016 Date of Last Review: September 2015
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationexenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationPatient Centric Treatment of Diabetes: The Role of GLP 1 Inhibitors
1:3 2:45pm Patient-Centric Treatment of Diabetes: The Role of GLP-1 Inhibitors SPEAKER Mark Molitch, MD Presenter Disclosure Information The following relationships exist related to this presentation:
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationErtugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy
Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion
More informationDulaglutide (LY ) for the treatment of type 2 diabetes
Expert Review of Clinical Pharmacology ISSN: 1751-2433 (Print) 1751-2441 (Online) Journal homepage: http://www.tandfonline.com/loi/ierj20 (LY-2189265) for the treatment of type 2 diabetes André J. Scheen
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationSteering Patients to Glycemic Control Using GLP-1 Receptor Agonists
Steering Patients to Glycemic Control Using GLP-1 Receptor Agonists IMPROVING T2DM OUTCOMES IN THE PHARMACY SETTING Release Date: July 31, 2015 Expiration Date: July 31, 2016 Presented by Creative Educational
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationClinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: Last Review Date: 02.
Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.19 Line of Business: HIM Revision Log See Important Reminder
More informationTREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017
TREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017 Outline Review treatment algorithms from ADA/ EASD & ACE/AACE. Review positive
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationADA and AACE Glycemic Targets
ADA and AACE Glycemic Targets HbA1C target should be individualized based on a number of factors including: Age Life expectancy Comorbidities Duration of diabetes Risk of hypoglycemia Patient motivation
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationThe Highlights of the AWARD Clinical Program FRANCESCO GIORGINO
The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO DEPARTMENT OF EMERGENCY AND ORGAN TRANSPLANTATION SECTION OF INTERNAL MEDICINE, ENDOCRINOLOGY, ANDROLOGY AND METABOLIC DISEASES Disclaimer
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationKeep Calm and Focus on the Evidence for the Management of Diabetes. Diabetes Update 2018
Keep Calm and Focus on the Evidence for the Management of Diabetes Diabetes Update 2018 Nicole C.Pezzino, PharmD, BCACP, CDE Assistant Professor, Wilkes University Pharmacist, Weis Markets Nicole.pezzino@wilkes.edu
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationPlease Complete the Pre-Activity Survey
Please Complete the Pre-Activity Survey This activity is supported through an educational grant from Novo Nordisk. Learning Objectives Upon completion of this educational activity, the participant should
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationA1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs
Butler University Digital Commons @ Butler University Undergraduate Honors Thesis Collection Undergraduate Scholarship 5-2017 A1c Reduction and Weight Loss in a Veteran Population Using GLP-1-RAs Shelby
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationdulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.
dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More information